Affinity Asset Advisors, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 14, 2024), Affinity Asset Advisors, LLC reported 69 stock positions worth $571.1 million. Its top holding was Apogee Therapeutics (APGE) at 6.9% of the portfolio, followed by Xenon Pharmaceuticals (XENE, 6.3%) and Madrigal Pharmaceuticals (MDGL, 5.4%). Compared with Q4 2023, it opened 23 new positions, sold out of 21, added to 25 and reduced 15. The biggest buy was Apogee Therapeutics (APGE, shares +10%) and the biggest sale an exit from Immunogen (IMGN).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001773195
- Portfolio Value
- $571.1M (Q1 2024)
- SEC Filing
- 0001999371-24-006067 ↗ filed May 14, 2024
Holdings Value
Holdings 69 stocks · $571.1M
| APGE Apogee Therapeutics Inc. | 6.89% | 592,093 | $39.3M | Add +10.2% |
| XENE Xenon Pharmaceuticals Inc. | 6.31% | 837,387 | $36.0M | Add +82.0% |
| MDGL Madrigal Pharmaceuticals Inc. | 5.38% | 115,000 | $30.7M | Add +15.0% |
| CRNX Crinetics Pharmaceuticals Inc. | 3.85% | 470,000 | $22.0M | Add +5.1% |
| AUTL Autolus Therapeutics PLC | 3.77% | 3,375,000 | $21.5M | Add +117.7% |
| CLDX Celldex Therapeutics Inc. | 3.75% | 510,000 | $21.4M | Add +27.5% |
| ACLX Arcellx Inc. | 3.65% | 300,000 | $20.9M | Reduce -11.8% |
| VERA Vera Therapeutics Inc. | 3.55% | 470,000 | $20.3M | New |
| INZY Inozyme Pharma Inc. | 3.54% | 2,642,519 | $20.2M | Add +40.1% |
| TEVA Teva Pharmaceutical-SP ADR | 3.46% | 1,400,000 | $19.8M | Reduce -26.3% |
| KURA Kura Oncology Inc. | 2.73% | 730,492 | $15.6M | Add +281.4% |
| SYRE Spyre Therapeutics Inc. | 2.72% | 410,000 | $15.6M | Reduce -20.8% |
| VRNA Verona Pharma Ltd. | 2.30% | 817,833 | $13.2M | Add +45.0% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 2.25% | 82,143 | $12.8M | New |
| CERE Cerevel Therapeutics Holding | 2.22% | 300,000 | $12.7M | Reduce -60.0% |
| NRIX Nurix Therapeutics Inc. | 2.09% | 810,253 | $11.9M | Add +17.4% |
| ATXS Astria Therapeutics Inc. | 2.08% | 845,606 | $11.9M | Reduce -42.3% |
| NUVL Nuvalent Inc. Class A | 1.97% | 150,000 | $11.3M | Reduce -14.3% |
| AXSM Axsome Therapeutics Inc. | 1.95% | 139,758 | $11.2M | Add +179.5% |
| APLS Apellis Pharmaceuticals Inc. | 1.70% | 165,000 | $9.7M | Add +120.0% |
| CNTA Centessa Pharmaceuticals Ltd. | 1.64% | 830,546 | $9.4M | Add +4.4% |
| IMVT Immunovant Inc. | 1.61% | 285,000 | $9.2M | Reduce -17.4% |
| CMPS Compass Pathways PLC | 1.50% | 1,027,868 | $8.6M | Add +86.9% |
| NARI Inari Medical Inc. | 1.47% | 175,000 | $8.4M | Add +775.0% |
| ESTA Establishment Labs Holdings | 1.47% | 164,589 | $8.4M | Reduce -27.9% |
| GERN Geron Corp. | 1.44% | 2,500,000 | $8.3M | New |
| MORF Morphic Holding Inc. | 1.39% | 225,000 | $7.9M | Add +427.3% |
| NAMS Newamsterdam Pharma Co. NV | 1.19% | 286,200 | $6.8M | Add +129.0% |
| ELEV Elevation Oncology Inc. | 1.14% | 1,268,825 | $6.5M | New |
| CATX Perspective Therapeutics Inc. | 1.06% | 5,100,000 | $6.1M | New |
| ABSI Absci Corp. | 1.02% | 1,025,000 | $5.8M | New |
| SVRA Savara Inc. | 1.00% | 1,150,000 | $5.7M | No change |
| CYTK Cytokinetics Inc. | 0.98% | 80,000 | $5.6M | Reduce -50.0% |
| PCVX Vaxcyte Inc. | 0.96% | 80,000 | $5.5M | Add +220.0% |
| ROIV Roivant Sciences Ltd. | 0.92% | 500,000 | $5.3M | No change |
| FULC Fulcrum Therapeutics Inc. | 0.91% | 550,339 | $5.2M | Add +340.3% |
| SWTX Springworks Therapeutics Inc. | 0.86% | 100,000 | $4.9M | No change |
| KRYS Krystal Biotech Inc. | 0.83% | 26,746 | $4.8M | Add +7.0% |
| MERSANA THERAPEUTICS INC | 0.78% | 1,000,000 | $4.5M | No change |
| CGEM Cullinan Therapeutics Inc. | 0.77% | 258,588 | $4.4M | Reduce -13.8% |
| MLYS Mineralys Therapeutics Inc. | 0.74% | 327,959 | $4.2M | New |
| VKTX Viking Therapeutics Inc. | 0.72% | 50,000 | $4.1M | Reduce -83.3% |
| RZLT Rezolute Inc. | 0.71% | 1,600,000 | $4.1M | New |
| MIRM Mirum Pharmaceuticals Inc. | 0.70% | 160,000 | $4.0M | Add +220.0% |
| MLTX Moonlake Immunotherapeutics | 0.66% | 75,000 | $3.8M | Add +5.7% |
| IMTX Immatics NV | 0.64% | 350,000 | $3.7M | Add +75.0% |
| ITCI Intra-Cellular Therapies Inc. | 0.61% | 50,000 | $3.5M | New |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.60% | 120,000 | $3.4M | New |
| NXTC Nextcure Inc. | 0.53% | 1,359,037 | $3.0M | New |
| TERN Terns Pharmaceuticals Inc. | 0.52% | 450,000 | $3.0M | Add +581.8% |
| PTGX Protagonist Therapeutics Inc. | 0.51% | 100,000 | $2.9M | New |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.45% | 250,000 | $2.6M | New |
| RGNX Regenxbio Inc. | 0.41% | 110,000 | $2.3M | New |
| ALKS Alkermes PLC | 0.36% | 75,000 | $2.0M | Reduce -79.0% |
| WVE Wave Life Sciences Ltd. | 0.31% | 286,585 | $1.8M | New |
| BSX Boston Scientific Corp. | 0.30% | 25,000 | $1.7M | New |
| KEZAR LIFE SCIENCES INC | 0.28% | 1,761,778 | $1.6M | New |
| BBIO Bridgebio Pharma Inc. | 0.27% | 50,000 | $1.5M | Reduce -37.5% |
| ARYD Arya Sciences Acquisition-A | 0.26% | 133,500 | $1.5M | New |
| TNGX Tango Therapeutics Inc. | 0.21% | 150,274 | $1.2M | Reduce -50.0% |
| ZURA Zura Bio Ltd. | 0.20% | 450,009 | $1.2M | New |
| TRML Tourmaline Bio Inc. | 0.20% | 50,000 | $1.1M | Reduce -26.6% |
| TVTX Travere Therapeutics Inc. | 0.17% | 125,000 | $964K | New |
| AVROBIO INC | 0.16% | 700,000 | $896K | Add +40.0% |
| PMN Promis Neurosciences Inc. | 0.09% | 265,958 | $508K | No change |
| QTTB Q32 Bio Inc. | 0.08% | 27,777 | $473K | New |
| CNTX Context Therapeutics Inc. | 0.08% | 328,817 | $454K | No change |
| PASG Passage Bio Inc. | 0.06% | 264,266 | $357K | New |
| AVTX Avalo Therapeutics Inc. | 0.04% | 10,000 | $218K | New |
Options reported separately and not counted above: XBI puts ($66.4M), MRNA puts ($42.6M), TEVA calls ($23.4M), IRWD calls ($9.0M), BBIO calls ($7.7M), GRITSTONE BIO INC puts ($6.1M), ALNY calls ($6.0M), RAPT THERAPEUTICS INC puts ($5.2M), GH calls ($5.2M), IMVT calls ($4.7M), CRSP calls ($4.4M), IBRX puts ($3.2M), and 6 more.
Other holdings (8): bonds, preferreds, convertibles and warrants · $44.0M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | 17,000,000 | $18.3M | No change |
| ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27) | NOTE 1.000% 9/1 · principal | 10,000,000 | $9.4M | New |
| OMEROS CORP (OMER 5.25 02/15/26) | NOTE 5.250% 2/1 · principal | 10,500,000 | $7.6M | Add +75.0% |
| COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) | NOTE 1.500% 4/1 · principal | 9,000,000 | $5.8M | Add +50.0% |
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 202,599 | $2.2M | Add +47.9% |
| IMTXW Immatics NV -CW | *W EXP 07/01/202 | 187,204 | $487K | No change |
| SAVAW Cassava Sciences Inc.-28 | *W EXP 11/15/202 | 24,200 | $98K | New |
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 75,000 | $22K | No change |
Total filed on the 13F, all lines: $615.1M.
Portfolio Sells Q4 2023 → Q1 2024
| IMGN Immunogen Inc. | Sold out | 0.00% | −8.81 |
| CBAY Cymabay Therapeutics Inc. | Sold out | 0.00% | −5.45 |
| CERE Cerevel Therapeutics Holding | Reduce -60.0% | 2.22% | −4.50 |
| LIANY Lianbio-ADR | Sold out | 0.00% | −3.57 |
| CYTK Cytokinetics Inc. | Reduce -50.0% | 0.98% | −1.84 |
| ALKS Alkermes PLC | Reduce -79.0% | 0.36% | −1.73 |
| IMVT Immunovant Inc. | Reduce -17.4% | 1.61% | −1.46 |
| MRTX Mirati Therapeutics Inc. | Sold out | 0.00% | −1.24 |
| DVAX Dynavax Technologies Corp. | Sold out | 0.00% | −0.89 |
| AZN Astrazeneca PLC-Spons ADR | Sold out | 0.00% | −0.85 |
| NUVL Nuvalent Inc. Class A | Reduce -14.3% | 1.97% | −0.75 |
| TEVA Teva Pharmaceutical-SP ADR | Reduce -26.3% | 3.46% | −0.73 |
| RLAY Relay Therapeutics Inc. | Sold out | 0.00% | −0.70 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −0.60 |
| EYPT Eyepoint Inc. | Sold out | 0.00% | −0.54 |
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −0.53 |
| VKTX Viking Therapeutics Inc. | Reduce -83.3% | 0.72% | −0.46 |
| TNGX Tango Therapeutics Inc. | Reduce -50.0% | 0.21% | −0.42 |
| BBIO Bridgebio Pharma Inc. | Reduce -37.5% | 0.27% | −0.41 |
| PEN Penumbra Inc. | Sold out | 0.00% | −0.40 |
| ADCT Adc Therapeutics SA | Sold out | 0.00% | −0.36 |
| ACLX Arcellx Inc. | Reduce -11.8% | 3.65% | −0.34 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −0.33 |
| ATXS Astria Therapeutics Inc. | Reduce -42.3% | 2.08% | −0.30 |
| NBIX Neurocrine Biosciences Inc. | Sold out | 0.00% | −0.28 |
| ALLO Allogene Therapeutics Inc. | Sold out | 0.00% | −0.27 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −0.23 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −0.19 |
| PBYI Puma Biotechnology Inc. | Sold out | 0.00% | −0.19 |
| TRML Tourmaline Bio Inc. | Reduce -26.6% | 0.20% | −0.18 |
| NUVB Nuvation Bio Inc. | Sold out | 0.00% | −0.08 |
| IFRX Inflarx NV | Sold out | 0.00% | −0.07 |
| ARAV Aravive Inc. | Sold out | 0.00% | −0.01 |
| CGEM Cullinan Therapeutics Inc. | Reduce -13.8% | 0.77% | +0.13 |
| ESTA Establishment Labs Holdings | Reduce -27.9% | 1.47% | +0.22 |
| SYRE Spyre Therapeutics Inc. | Reduce -20.8% | 2.72% | +0.37 |
Portfolio Buys Q4 2023 → Q1 2024
| APGE Apogee Therapeutics Inc. | Add +10.2% | 6.89% | +3.72 |
| VERA Vera Therapeutics Inc. | New | 3.55% | +3.55 |
| ONC Beone Medicines Ltd.-ADR | New | 2.25% | +2.25 |
| KURA Kura Oncology Inc. | Add +281.4% | 2.73% | +2.15 |
| INZY Inozyme Pharma Inc. | Add +40.1% | 3.54% | +1.85 |
| XENE Xenon Pharmaceuticals Inc. | Add +82.0% | 6.31% | +1.83 |
| AUTL Autolus Therapeutics PLC | Add +117.7% | 3.77% | +1.66 |
| GERN Geron Corp. | New | 1.44% | +1.44 |
| NARI Inari Medical Inc. | Add +775.0% | 1.47% | +1.20 |
| ELEV Elevation Oncology Inc. | New | 1.14% | +1.14 |
| MORF Morphic Holding Inc. | Add +427.3% | 1.39% | +1.13 |
| AXSM Axsome Therapeutics Inc. | Add +179.5% | 1.95% | +1.11 |
| CATX Perspective Therapeutics Inc. | New | 1.06% | +1.06 |
| ABSI Absci Corp. | New | 1.02% | +1.02 |
| NAMS Newamsterdam Pharma Co. NV | Add +129.0% | 1.19% | +0.89 |
| APLS Apellis Pharmaceuticals Inc. | Add +120.0% | 1.70% | +0.75 |
| MLYS Mineralys Therapeutics Inc. | New | 0.74% | +0.74 |
| FULC Fulcrum Therapeutics Inc. | Add +340.3% | 0.91% | +0.73 |
| RZLT Rezolute Inc. | New | 0.71% | +0.71 |
| PCVX Vaxcyte Inc. | Add +220.0% | 0.96% | +0.63 |
| ITCI Intra-Cellular Therapies Inc. | New | 0.61% | +0.61 |
| ARWR Arrowhead Pharmaceuticals Inc. | New | 0.60% | +0.60 |
| NRIX Nurix Therapeutics Inc. | Add +17.4% | 2.09% | +0.58 |
| NXTC Nextcure Inc. | New | 0.53% | +0.53 |
| PTGX Protagonist Therapeutics Inc. | New | 0.51% | +0.51 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +5.1% | 3.85% | +0.49 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +15.0% | 5.38% | +0.49 |
| CMPS Compass Pathways PLC | Add +86.9% | 1.50% | +0.48 |
| BBOT Bridgebio Oncology Therapeut | New | 0.45% | +0.45 |
| TERN Terns Pharmaceuticals Inc. | Add +581.8% | 0.52% | +0.43 |
| RGNX Regenxbio Inc. | New | 0.41% | +0.41 |
| CLDX Celldex Therapeutics Inc. | Add +27.5% | 3.75% | +0.39 |
| MIRM Mirum Pharmaceuticals Inc. | Add +220.0% | 0.70% | +0.39 |
| WVE Wave Life Sciences Ltd. | New | 0.31% | +0.31 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +4.4% | 1.64% | +0.30 |
| BSX Boston Scientific Corp. | New | 0.30% | +0.30 |
| KEZAR LIFE SCIENCES INC | New | 0.28% | +0.28 |
| ARYD Arya Sciences Acquisition-A | New | 0.26% | +0.26 |
| ZURA Zura Bio Ltd. | New | 0.20% | +0.20 |
| IMTX Immatics NV | Add +75.0% | 0.64% | +0.20 |
| KRYS Krystal Biotech Inc. | Add +7.0% | 0.83% | +0.18 |
| TVTX Travere Therapeutics Inc. | New | 0.17% | +0.17 |
| QTTB Q32 Bio Inc. | New | 0.08% | +0.08 |
| PASG Passage Bio Inc. | New | 0.06% | +0.06 |
| AVTX Avalo Therapeutics Inc. | New | 0.04% | +0.04 |
| AVROBIO INC | Add +40.0% | 0.16% | +0.01 |
| VRNA Verona Pharma Ltd. | Add +45.0% | 2.30% | −0.07 |
| MLTX Moonlake Immunotherapeutics | Add +5.7% | 0.66% | −0.25 |
Options Activity Q4 2023 → Q1 2024
| XBI SS SPDR S&P Biotech ETF | put | New | 700,000 | $66.4M |
| MRNA Moderna Inc. | put | New | 400,000 | $42.6M |
| TEVA Teva Pharmaceutical-SP ADR | call | Add +18.2% | 1,655,000 | $23.4M |
| IRWD Ironwood Pharmaceuticals Inc. | call | New | 1,029,500 | $9.0M |
| BBIO Bridgebio Pharma Inc. | call | New | 250,000 | $7.7M |
| EYPT Eyepoint Inc. | put | Sold out | 320,100 | $7.4Mbefore exit |
| GRITSTONE BIO INC | put | New | 2,390,600 | $6.1M |
| ALNY Alnylam Pharmaceuticals Inc. | call | Add +33.3% | 40,000 | $6.0M |
| RAPT THERAPEUTICS INC | put | New | 577,100 | $5.2M |
| GH Guardant Health Inc. | call | New | 250,000 | $5.2M |
| IMVT Immunovant Inc. | call | New | 144,400 | $4.7M |
| CRSP Crispr Therapeutics AG | call | New | 65,000 | $4.4M |
| GPCR Structure Therapeutics Inc. | call | Sold out | 100,000 | $4.1Mbefore exit |
| CRNX Crinetics Pharmaceuticals Inc. | put | Sold out | 94,300 | $3.4Mbefore exit |
| IBRX Immunitybio Inc. | put | New | 589,400 | $3.2M |
| FLNA Filana Therapeutics Inc. | call | Sold out | 121,000 | $2.7Mbefore exit |
| FULC Fulcrum Therapeutics Inc. | call | New | 275,000 | $2.6M |
| ESTA Establishment Labs Holdings | call | Reduce -77.8% | 50,000 | $2.5M |
| AKRO Akero Therapeutics Inc. | call | New | 75,000 | $1.9M |
| APLS Apellis Pharmaceuticals Inc. | call | Sold out | 25,000 | $1.5Mbefore exit |
| ANVS Annovis Bio | put | New | 72,900 | $868K |
| ALKS Alkermes PLC | put | Sold out | 27,000 | $749Kbefore exit |
| RAPT THERAPEUTICS INC | call | New | 60,000 | $539K |
| GLYCOMIMETICS INC | put | New | 142,300 | $427K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q4 2023 → Q1 2024
| ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27) | NOTE 1.000% 9/1 · principal | New | 10,000,000 | $9.4M |
| OMEROS CORP (OMER 5.25 02/15/26) | NOTE 5.250% 2/1 · principal | Add +75.0% | 10,500,000 | $7.6M |
| COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) | NOTE 1.500% 4/1 · principal | Add +50.0% | 9,000,000 | $5.8M |
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | Add +47.9% | 202,599 | $2.2M |
| SAVAW Cassava Sciences Inc.-28 | *W EXP 11/15/202 | New | 24,200 | $98K |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $2.0B | ROIV, APGE, SYRE, XENE, ERAS |
| Q1 2026 | 90 | $1.7B | APGE, XENE, ERAS, INSM, ROIV |
| Q4 2025 | 80 | $1.3B | APGE, INSM, ABVX, VTYX, XENE |
| Q3 2025 | 80 | $1.0B | VRNA, INSM, SPY, XENE, MDGL |
| Q2 2025 | 71 | $648.9M | VRNA, INSM, XENE, ACLX, BPMC |
| Q1 2025 | 75 | $603.1M | XENE, APGE, VRNA, ACLX, ALKS |
| Q4 2024 | 68 | $588.3M | XENE, APGE, ACLX, ALKS, TEVA |
| Q3 2024 | 70 | $601.0M | XENE, APGE, NUVL, ACLX, ALKS |
| Q2 2024 | 78 | $576.0M | XENE, APGE, MDGL, ACLX, TEVA |
| Q1 2024 | 69 | $571.1M | APGE, XENE, MDGL, CRNX, AUTL |